Purpose: Fixed-combination medication to treat glaucoma can reduce intraocular pressure (IOP) without negative effects of concomitant medication. Tafluprost/timolol fixed-combination ophthalmic solution (TTFC) has bee...Purpose: Fixed-combination medication to treat glaucoma can reduce intraocular pressure (IOP) without negative effects of concomitant medication. Tafluprost/timolol fixed-combination ophthalmic solution (TTFC) has been reported to show similar effectiveness in lowering IOP, compared with concomitant use of its component drugs, tafluprost and timolol. However, the difference in IOP-lowering effects between TTFC and concomitant use of tafluprost and gel-forming timolol is unknown. Hence, we conducted this switching study from tafluprost and gel-forming timolol to TTFC in glaucoma patients undergoing multi-drug therapy. Design: Multi-center, open-label, interventional clinical study. Methods: Twenty-eight patients (28 eyes;safety analysis set) with primary open-angle glaucoma and ocular hypertension, who had completed the 4-week-concomitant phase of tafluprost and gel-forming timolol, were treated for 8 weeks with TTFC. IOP, adherence, ocular surface safety, and the usability of ophthalmic solution were compared before and after switching. This study was approved by the ethics committees of Kitasato University Hospital and all other study sites. All patients provided written informed consent to participate. Results: IOP at 8 weeks after switching was significantly lower than before switching (P = 0.0001) in the efficacy analysis set (n = 24). The self-reported adherence rate remained high after switching;moreover, there was no meaningful change in ocular surface safety. Patient questionnaires regarding usability of medication revealed that 85.7% of patients preferred their instillation prescription after switching, including TTFC. Among the safety analysis set (n = 28), no adverse events were reported in relation to the study drug. Conclusion: TTFC showed greater IOP reduction than concomitant therapy. Thus, TTFC may be a better option in glaucoma patients than concomitant therapy.展开更多
The reccnt Alcatel Lucent failure is an example of how many mergers run into considerable implementing difficulties in the months following their launch. Despite promising perspectives,no coherent whole seems to come ...The reccnt Alcatel Lucent failure is an example of how many mergers run into considerable implementing difficulties in the months following their launch. Despite promising perspectives,no coherent whole seems to come out of the merger,just as anticipated synergies have a hard time materializing.展开更多
为了提高聚能战斗部对水中目标的毁伤威力,提出形成串联爆炸成型弹丸(Explosively Formed Projectile,EFP)的组合药型罩战斗部结构。利用平板抛掷和圆筒压垮公式建立组合药型罩EFP速度分析模型,并使用AUTODYN-2D软件对EFP成型和入水毁...为了提高聚能战斗部对水中目标的毁伤威力,提出形成串联爆炸成型弹丸(Explosively Formed Projectile,EFP)的组合药型罩战斗部结构。利用平板抛掷和圆筒压垮公式建立组合药型罩EFP速度分析模型,并使用AUTODYN-2D软件对EFP成型和入水毁伤过程进行数值模拟,研究组合药型罩结构参数对串联EFP成型的影响,证明其在水中高效的侵彻性能。研究结果表明:理论与数值模拟计算得到的EFP速度基本吻合,最大误差不超过10%;组合药型罩分离形成串联EFP是由于内外罩不同的材料和结构组合使罩微元从接触面处开始形成较大的速度差所引起的;随着内罩直径的增大,内外罩形成的EFP速度同时减小,长径比分别增大与减小;单独增大内外罩外曲率半径与罩顶壁厚,对应罩成型的EFP性能变化规律和单一药型罩相同,但另一罩成型EFP的长径比均减小或分别减小与增大,速度变化幅度较小;组合药型罩串联EFP侵彻4倍装药直径的水后,动能衰减率较双层药型罩降低21.55%,剩余速度提高5.77%,且随着侵彻距离的增加该差距进一步扩大。展开更多
文摘Purpose: Fixed-combination medication to treat glaucoma can reduce intraocular pressure (IOP) without negative effects of concomitant medication. Tafluprost/timolol fixed-combination ophthalmic solution (TTFC) has been reported to show similar effectiveness in lowering IOP, compared with concomitant use of its component drugs, tafluprost and timolol. However, the difference in IOP-lowering effects between TTFC and concomitant use of tafluprost and gel-forming timolol is unknown. Hence, we conducted this switching study from tafluprost and gel-forming timolol to TTFC in glaucoma patients undergoing multi-drug therapy. Design: Multi-center, open-label, interventional clinical study. Methods: Twenty-eight patients (28 eyes;safety analysis set) with primary open-angle glaucoma and ocular hypertension, who had completed the 4-week-concomitant phase of tafluprost and gel-forming timolol, were treated for 8 weeks with TTFC. IOP, adherence, ocular surface safety, and the usability of ophthalmic solution were compared before and after switching. This study was approved by the ethics committees of Kitasato University Hospital and all other study sites. All patients provided written informed consent to participate. Results: IOP at 8 weeks after switching was significantly lower than before switching (P = 0.0001) in the efficacy analysis set (n = 24). The self-reported adherence rate remained high after switching;moreover, there was no meaningful change in ocular surface safety. Patient questionnaires regarding usability of medication revealed that 85.7% of patients preferred their instillation prescription after switching, including TTFC. Among the safety analysis set (n = 28), no adverse events were reported in relation to the study drug. Conclusion: TTFC showed greater IOP reduction than concomitant therapy. Thus, TTFC may be a better option in glaucoma patients than concomitant therapy.
文摘The reccnt Alcatel Lucent failure is an example of how many mergers run into considerable implementing difficulties in the months following their launch. Despite promising perspectives,no coherent whole seems to come out of the merger,just as anticipated synergies have a hard time materializing.
文摘为了提高聚能战斗部对水中目标的毁伤威力,提出形成串联爆炸成型弹丸(Explosively Formed Projectile,EFP)的组合药型罩战斗部结构。利用平板抛掷和圆筒压垮公式建立组合药型罩EFP速度分析模型,并使用AUTODYN-2D软件对EFP成型和入水毁伤过程进行数值模拟,研究组合药型罩结构参数对串联EFP成型的影响,证明其在水中高效的侵彻性能。研究结果表明:理论与数值模拟计算得到的EFP速度基本吻合,最大误差不超过10%;组合药型罩分离形成串联EFP是由于内外罩不同的材料和结构组合使罩微元从接触面处开始形成较大的速度差所引起的;随着内罩直径的增大,内外罩形成的EFP速度同时减小,长径比分别增大与减小;单独增大内外罩外曲率半径与罩顶壁厚,对应罩成型的EFP性能变化规律和单一药型罩相同,但另一罩成型EFP的长径比均减小或分别减小与增大,速度变化幅度较小;组合药型罩串联EFP侵彻4倍装药直径的水后,动能衰减率较双层药型罩降低21.55%,剩余速度提高5.77%,且随着侵彻距离的增加该差距进一步扩大。
